Ligand Pharma Statistics
Ligand Pharma (LGDN) Stock Statistics & Valuation Metrics
Total Valuation
Ligand Pharma has a market cap or net worth of EUR 5.66B. The enterprise value is EUR 6.94B.
- Market Cap
- EUR 5.66B
- Enterprise Value
- EUR 6.94B
Share Statistics
Ligand Pharma has 20,002,987 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 20,002,987
- Owned by Insiders
- 2.48%
- Owned by Institutions
- 92.82%
Financial Efficiency
Ligand Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 2.42%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 2.42%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 5.70M
- Profits Per Employee
- 2.65M
- Employee Count
- 47
- Asset Turnover
- 0.17
- Inventory Turnover
- 0.72
Valuation Ratios
The current PE Ratio of Ligand Pharma is 122.33. Ligand Pharma’s PEG ratio is 14.62.
- PE Ratio
- 122.33
- PS Ratio
- 24.97
- PB Ratio
- 6.58
- Price to FCF
- 69.98
- Price to Operating Cash Flow
- 69.53
- PEG Ratio
- 14.62
Income Statement
In the last 12 months, Ligand Pharma had revenue of 268.09M and earned 124.45M in profits. Earnings per share was 6.44.
- Revenue
- 268.09M
- Gross Profit
- 261.50M
- Operating Income
- 47.20M
- Pretax Income
- 158.96M
- Net Income
- 124.45M
- EBITDA
- 192.74M
- Earnings Per Share (EPS)
- 6.44
Cash Flow
In the last 12 months, operating cash flow was 90.96M and capital expenditures -405,000, giving a free cash flow of 90.56M billion.
- Operating Cash Flow
- 90.96M
- Free Cash Flow
- 90.56M
- Free Cash Flow per Share
- 4.54
Dividends & Yields
Ligand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.43%
- Earnings Yield
- 0.81%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- 55.68%
- 50-Day Moving Average
- 257.72
- 200-Day Moving Average
- 218.15
- Relative Strength Index (RSI)
- 55.67
- Average Volume (3m)
- 27
Important Dates
Ligand Pharma upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Ligand Pharma as a current ratio of 22.23, with Debt / Equity ratio of 44.39%
- Current Ratio
- 22.23
- Quick Ratio
- 21.98
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 1.43
- Interest Coverage Ratio
- 10.01
Taxes
In the past 12 months, Ligand Pharma has paid 34.51M in taxes.
- Income Tax
- 34.51M
- Effective Tax Rate
- 0.22
Enterprise Valuation
Ligand Pharma EV to EBITDA ratio is 92.33, with an EV/FCF ratio of 82.11.
- EV to Sales
- 29.29
- EV to EBITDA
- 92.33
- EV to Free Cash Flow
- 82.11
- EV to Operating Cash Flow
- 81.75
Balance Sheet
Ligand Pharma has EUR 447.39M in cash and marketable securities with EUR 1.15B in debt, giving a net cash position of -EUR 706.81M billion.
- Cash & Marketable Securities
- EUR 447.39M
- Total Debt
- EUR 1.15B
- Net Cash
- -EUR 706.81M
- Net Cash Per Share
- -EUR 35.34
- Tangible Book Value Per Share
- EUR 22.64
Margins
Gross margin is 107.11%, with operating margin of 11.91%, and net profit margin of 20.27%.
- Gross Margin
- 107.11%
- Operating Margin
- 11.91%
- Pretax Margin
- 20.77%
- Net Profit Margin
- 20.27%
- EBITDA Margin
- 31.73%
- EBIT Margin
- 21.46%
Analyst Forecast
The average price target for Ligand Pharma is EUR 328.82, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 328.82
- Price Target Upside
- 20.01% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- -2.38%
- EPS Growth Forecast
- 29.65%
Scores
- Smart Score
- 9
- AI Score
- ―
